



Vivimed

Date: November 30, 2011

To
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (East)
Mumbai- 400051

Dear Sir/Madam,


Sub: Acquisition of Uquifa Spain and Uquifa Mexico: Reg.
Ref: Clause 36 of Listing Agreement

With reference to captioned subject and pursuant to Clause 36 of Listing Agreement entered into with the stock exchange, we would like to inform that:

Vivimed Labs today has acquired Uquifa, a 75-year-old manufacturer of pharma APIs and intermediates with operations in Spain and Mexico. In a move to bring in strategic growth into its product mix and expand the footprint in Europe and the Americas, Vivimed Labs has taken a measured stride with the acquisition of Uquifa Spain and Uquifa Mexico.

This well considered move would strengthen Vivimed Labs current position in pharma APIs and intermediates while significantly improving the cost competitiveness of Uquifa. Complementing each other's needs and growth plans the acquisition envisages being a healthy, *'two-way opportunity pipeline'* for Vivimed. While Uquifa gets the supply side efficiencies and knowledge base of Vivimed in pharma, Vivimed would leverage the preeminent position of Uquifa in APIs and their robust pipeline of filings to accelerate growth across Europe and the Americas in the next five years.

Vivimed also believes the acquisition of Uquifa will add to its multi-geographical locations and knowledge base. This will fundamentally mean greater comfort levels for customers and channel partners. The Uquifa acquisition in Europe comes after 2008, post a successful acquisition and integration of James Robinson, UK.





Vivimed

Commenting on the Uquifa acquisition, Santosh Varalwar, MD, Vivimed Labs observed:

"Multi- geographical locations spell stability and cement long term relationships with customers and channel partners. With Uquifa, Vivimed will have a footprint into LATAM and deeper into Europe. India – facing efficiencies and Uquifa's strengths will be seamlessly aligned in the new dispensation. Uquifa's preeminent position in APIs, combined with Vivimed's supply chain efficiencies means enhanced competitiveness for Uquifa and swifter broadening of customer base.

The Vivimed group of companies has experience in developing a marquee customer base. It has a significant number of blue chip healthcare customers both in the ethical and generic pharmaceutical sectors. Amongst its list of customers are some of the top 10 innovator companies and top 10 pharma companies in the world. An established player in the manufacture of pharma formulations, it operates from multiple locations in India.

Uquifa will become the API division of the Vivimed group.

The Corporate M&A advisory for this acquisition was provided by Mr. Sunil Arab of M/s Srimahi Ltd., a cross-border M&A advisory firm based in Hong Kong"

This is for your information and record.

Thanking You

Yours Truly,

For Vivimed Labs Limited


Fahim Aslam Khan
Company Secretary

